Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis

Eric Huang, BSc; Clement C. Zai, PhD; Amanda Lisoway, BSc; Malgorzata Maciukiewicz, PhD; Daniel Felsky, BSc; Arun K. Tiwari, PhD; Jeffrey R. Bishop, MSc; PharmD, MSc; Masashi Ikeda, MD, PhD; Patricio Molero, MD, PhD; Felipe Ortuno, MD, PhD; Stefano Porcelli, MD; Jerzy Samochowiec, MD, PhD; Pawel Mierzejewski, MD, PhD; Shugui Gao, MD; Benedicto Crespo-Facorro, MD, PhD; José M Pelayo-Terán, MD, PhD; Harpreet Kaur, PhD; Ritushree Kukreti, PhD; Herbert Y. Meltzer, MD; Jeffrey A. Lieberman, MD; Steven G. Potkin, MD; Daniel J. Müller, MD, PhD; James L. Kennedy, MD

Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada (Mr Huang, Dr Zai, Ms Lisoway, Dr Maciukiewicz, Mr Felsky, Dr Tiwari, Dr Müller, and Dr Kennedy); Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN (Dr Bishop); Department of Psychiatry, Fujita Health University, Toyoake, Aichi, Japan (Dr Ikeda); Departamento de Psiquiatria, Clínica Universidad de Navarra, Pamplona, Spain (Drs Molero and Ortuno); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Dr Porcelli); Department of Psychiatry, Pomeranian Medical University, Szczecin, Poland (Dr Samochowiec); Department of Pharmacology, Institute of Psychiatry and Neurology, Warsaw, Poland (Dr Mierzejewski); Department of Psychiatry, Ningbo Kangning Hospital, Ningbo, China (Dr Gao); Department of Psychiatry, CIBERSAM, University Hospital Marqués de Valdecilla- IDIVAL, School of Medicine, University of Cantabria, Santander, Spain (Dr Pelayo-Terán); Institute of Genomics and Integrative Biology, Delhi, India (Drs Kaur and Kukreti); Feinberg School of Medicine, Northwestern University, Chicago, IL (Dr Meltzer); Department of Psychiatry, Columbia University Medical Center, New York, NY (Dr Lieberman); Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA (Dr Potkin).

Correspondence: James L. Kennedy, MD, FRCPC, FRSC, Director, Neuroscience Research, Head, Neurogenetics Section, Centre for Addiction and Mental Health (CAMH); Professor and Co-Director Div. of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, Canada (jkennedy@camh.ca).
Abstract

Background: The catechol-O-methyltransferase (COMT) enzyme plays a crucial role in dopamine degradation, and the COMT Val158Met polymorphism (rs4680) is associated with significant differences in enzymatic activity and consequently dopamine concentrations in the prefrontal cortex. Multiple studies have analyzed the COMT Val158Met variant in relation to antipsychotic response. Here, we conducted a meta-analysis examining the relationship between COMT Val158Met and antipsychotic response. Methods: Searches using PubMed, Web of Science, and PsycINFO databases (03/01/2015) yielded 23 studies investigating COMT Val158Met variation and antipsychotic response in schizophrenia and schizo-affective disorder. Responders/nonresponders were defined using each study's original criteria. If no binary response definition was used, authors were asked to define response according to at least 30% Positive and Negative Syndrome Scale score reduction (or equivalent in other scales). Analysis was conducted under a fixed-effects model. Results: Ten studies met inclusion criteria for the meta-analysis. Five additional antipsychotic-treated samples were analyzed for Val158Met and response and included in the meta-analysis (N = 1416). Met/Met individuals were significantly more likely to respond than Val-carriers (P = .039, OR_Met/Met = 1.37, 95% CI: 1.02–1.85). Met/Met patients also experienced significantly greater improvement in positive symptoms relative to Val-carriers (P = .030, SMD = 0.24, 95% CI: 0.024–0.46). Posthoc analyses on patients treated with atypical antipsychotics (n = 1207) showed that Met/Met patients were significantly more likely to respond relative to Val-carriers (P = .098, OR_Met/Met = 1.54, 95% CI: 1.11–2.14), while no difference was observed for typical antipsychotic-treated patients (n = 155) (P = .65). Conclusions: Our findings suggest that the COMT Val158Met polymorphism is associated with response to antipsychotics in schizophrenia and schizo-affective disorder patients. This effect may be more pronounced for atypical antipsychotics.

Keywords: COMT, Val158Met, antipsychotics, schizophrenia, clinical response

Introduction

Schizophrenia (SCZ) is a debilitating neurodevelopmental disorder with high heritability (~0.8) (McGuffin et al., 1995). While antipsychotic drugs are currently the most effective treatment, clinical response varies significantly between patients, with an overall response rate of only 50% (Lieberman et al., 2005). The field of pharmacogenomics aims to optimize treatment at the individual level by leveraging our knowledge of how genetic variants influence clinical response. Since all antipsychotics target the dopamine (DA) system to various extents by binding to dopamine D2 receptors, pharmacogenetics studies have largely focused on DA system-related genes, including those encoding the dopamine D2 receptor (DRD2) and catechol-O-methyltransferase (COMT). Previous studies have identified associations for genes such as DRD2 and DRD3 (dopamine D3 receptor) in relation to response to antipsychotics (Hwang et al., 2010; Zhang et al., 2010). Other genes implicated in response include 5-HT2A and 5-HT2C (Pouget and Müller, 2014).

The COMT gene is located within the 22q11 chromosomal locus, a region highly implicated in SCZ risk (Badner and Gershon, 2002; Lewis et al., 2003). The COMT enzyme plays a significant role in cortical DA degradation (Lachman et al., 1996). The majority of pharmacogenetics studies examining COMT in relation to antipsychotic response have focused on the functional variant Val158Met (rs4680). Other putatively functional variants have also been examined, though relatively infrequently (Chen et al., 2004; Molero et al., 2007). The Val158Met variant is located within exon 4 of the COMT gene and involves a G-to-A nucleotide substitution, leading to a valine (Val) to methionine (Met) substitution at codon 158. The Met-allele form of the enzyme has lower thermostability and has been observed to exhibit reduced enzymatic activity, contributing to increased levels of cortical dopamine (Chen et al., 2004); the Met/Met homozygotes have 3- to 4-fold lower enzymatic activity than the Val/Val homozygote, while the heterozygote has intermediate activity (Chen et al., 2004).

Studies of COMT Val158Met and antipsychotic response in SCZ and schizo-affective disorder have yielded mixed results. A number of studies have observed that the Met-allele is associated with better overall clinical response as well as greater improvement in negative symptoms and cognitive abilities such as working memory (Bertolino et al., 2004, 2007; Molero et al., 2007; Woodward et al., 2007; Pelayo-Terán et al., 2011). However, other studies have either been unable to replicate these findings (Yamanouchi et al., 2003; Gao et al., 2012; Tybura et al., 2012; Bishop et al., 2015) or observed the opposite effect, with the Met-allele predicting nonresponse to antipsychotic therapy (Illi et al., 2003; Porcelli et al., 2009). In an effort to clarify the COMT Val158Met variant’s role in antipsychotic response, we conducted a meta-analysis of the existing literature plus additional data. In our primary analysis, we examined the association between this variant and both binary and continuous measures of response to antipsychotics. The meta-analysis focused solely on clinical response to antipsychotics, since the overwhelming majority of Val158Met pharmacogenetics studies examined this phenotype.

Methods and Materials

Literature Search

A literature search was conducted for articles written in English published up to March 1, 2015, examining the COMT Val158Met variant and antipsychotic response in SCZ and schizo-affective disorder patients. We performed searches on PubMed, PsycINFO, and Web of Science using all combinations of the key terms ‘COMT,’ ‘Catechol-O-methyltransferase,’ and ‘Val158Met,’ with the phrases ‘antipsychotic response’ and ‘SCZ treatment response.’ Criteria for inclusion in the current study consisted of: (1) the association between the COMT Val158Met polymorphism and antipsychotic response was assessed; (2) the patients were diagnosed with SCZ or schizoaffective disorder based on DSM-III, DSM-IV, DSM-V, or ICD-10 criteria and their diagnoses were verified through a standardized structured clinical interview; (3) antipsychotic response was evaluated according to a standardized clinical rating scale, such as the Brief Psychiatric Rating Scale (BPRS) or the Positive and Negative Syndrome Scale (PANSS); (4) drug response (symptom severity) was evaluated at a minimum of 2 time points, one of which was directly prior to starting antipsychotic therapy; and (5) patients were evaluated for a minimum
of 2 weeks for response to treatment. Studies investigating non-clinical aspects of response, such as cognitive response, were excluded. We also searched through the reference sections of articles meeting these criteria to find other articles fit for inclusion. Authors were contacted for data when the data necessary for analysis was not reported in articles that met inclusion criteria.

In total, the literature search yielded 23 peer-reviewed articles published before March 1, 2015. Two of these articles were identified through searching the reference sections of the other 21 articles (Porcelli et al., 2009; Kang et al., 2010). The literature search process is outlined in Figure 1. In total, 15 articles met inclusion criteria for the current study. However, 11 of the 15 studies did not have group-level data (ie, number of responders/nonresponders) available online (Molero et al., 2007; Ikeda et al., 2008; Fijal et al., 2009; Need et al., 2009; Porcelli et al., 2009; Kang et al., 2010; Gao et al., 2012; Tybura et al., 2012; Zhao et al., 2012; Bishop et al., 2015; Bosia et al., 2015). Another 2 studies focused on first-episode psychosis and did not provide the response/nonresponse data for its subset of SCZ or schizo-affective disorder patients (Pelayo-Terán et al., 2011; Prata et al., 2012). We attempted to contact each of these groups and obtained data from 7 of these studies (Molero et al., 2007; Ikeda et al., 2008; Porcelli et al., 2009; Pelayo-Terán et al., 2011; Gao et al., 2012; Tybura et al., 2012; Bishop et al., 2015). The studies for which we were unable to retrieve the required data were excluded (Fijal et al., 2009; Need et al., 2009; Kang et al., 2010; Prata et al., 2012; Zhao et al., 2012; Bosia et al., 2015). We added data from 5 additional samples that our group has published on previously (Hwang et al., 2005; Prata et al., 2012; Zai et al., 2012; Tiwari et al., 2013; Gonçalves et al., 2014) to these 10 studies’ samples to give a total of 15 samples (n=#{1416}). Two of these samples had previously been analyzed for Val158Met and antipsychotic response (Nolan et al., 2006), while the other 3 had not been. Figure 1 illustrates the literature search process. The demographic and clinical characteristics of the 15 samples are described in Table 1. All 15 samples included data for the number of responders and nonresponders. Ten of these samples also had data for change in total score (%). Of these 10 samples, 6 further included positive and negative symptom subscale score change data. We later contacted the authors for studies with a mix of atypical and typical-antipsychotic-treated patients to obtain response data for each antipsychotic type separately.

**Subjects from Toronto Samples**

The 5 samples from Toronto in this analysis included Toronto samples (TS)1–5. TS1 (Lieberman, N = 32) was collected at 4 psychiatric state hospitals in New York and North Carolina. These patients met DSM-IV criteria for chronic SCZ and or schizo-affective disorder. They exhibited suboptimal response to prior treatment, defined primarily by persistent positive symptoms and poor functioning for the past 2 years. The patients were recruited as part of a 14-week, randomized, double-blinded study and response was evaluated using the PANSS scale. This sample is also described in greater detail elsewhere (Volavka et al., 2004). TS2 (Muller, N = 39) was collected at Charité University Medicine, Berlin, Germany. Patients were diagnosed with SCZ or schizo-affective disorder according to DSM-IV or ICD-10 criteria and treated with several different antipsychotics. This sample is described in more detail elsewhere (Muller et al., 2012). TS3 (Meltzer, N = 90), 4 (Lieberman, N = 90), and 5 (Potkin, N = 32) were collected from Case Western Reserve University in Cleveland, Ohio, Zucker Hillside Hospital in Glen Oaks, New York, and University of California at Irvine, respectively. Subjects from TS3-5 had DSM-III-R or DSM-IV diagnoses of SCZ and met criteria for treatment refractoriness or intolerance to traditional antipsychotic therapy. After a 2- to 4-week washout period, patients were treated with clozapine and evaluated prospectively for 6 months, during which blood levels of clozapine were monitored to confirm treatment adherence. Treatment response was evaluated using the 18-item BPRS (Overall and Gorham, 1962) at the beginning and end of treatment. These samples are described in greater detail elsewhere (Hwang et al., 2005). Analysis of response in each of these samples is discussed in the section “Definition of Response.” The ethnicities of patients from all 5 samples are described in Table 1.
Table 1. Characteristics of Studies Investigating the Association between COMT Polymorphism Val158Met and Antipsychotic Drug Response in Schizophrenia/Schizo-Affective Disorder Patients

<table>
<thead>
<tr>
<th>Study/Sample</th>
<th>N</th>
<th>Ethnicity</th>
<th>MAF</th>
<th>Design</th>
<th>Medication</th>
<th>Response Criteria</th>
<th>Responders/Nonresponders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bertolino et al., 2004</td>
<td>30</td>
<td>EU</td>
<td>0.45</td>
<td>Prospective</td>
<td>Olanzapine</td>
<td>PANSS 30% ↓</td>
<td>14 / 16</td>
</tr>
<tr>
<td>Bertolino et al., 2007</td>
<td>29</td>
<td>EU</td>
<td>0.59</td>
<td>Prospective</td>
<td>Olanzapine</td>
<td>PANSS 30% ↓</td>
<td>14 / 15</td>
</tr>
<tr>
<td>Bishop et al., 2014*</td>
<td>61</td>
<td>EU, AA, AS, HS, O</td>
<td>0.41</td>
<td>Prospective</td>
<td>Various</td>
<td>BPRS 35% ↓</td>
<td>10 / 51</td>
</tr>
<tr>
<td>Toronto Sample 1</td>
<td>58</td>
<td>EU, AA, O</td>
<td>0.38</td>
<td>Prospective, Randomized</td>
<td>Various</td>
<td>PANSS 30% ↓</td>
<td>10 / 48</td>
</tr>
<tr>
<td>Gao et al., 2012</td>
<td>83</td>
<td>AS</td>
<td>0.39</td>
<td>Prospective</td>
<td>Risperidone</td>
<td>PANSS 30% ↓</td>
<td>69 / 14</td>
</tr>
<tr>
<td>Toronto Sample 2</td>
<td>89</td>
<td>EU, AA</td>
<td>0.51</td>
<td>Naturalistic</td>
<td>Risperidone</td>
<td>CGI 2 or less</td>
<td>69 / 48</td>
</tr>
<tr>
<td>Gupta et al., 2009</td>
<td>117</td>
<td>SI</td>
<td>0.37</td>
<td>Naturalistic</td>
<td>Various</td>
<td>BPRS 35% ↓</td>
<td>31 / 59</td>
</tr>
<tr>
<td>Toronto Sample 3*</td>
<td>90</td>
<td>EU, AA</td>
<td>0.44</td>
<td>Prospective</td>
<td>Various</td>
<td>Clozapine</td>
<td>55 / 35</td>
</tr>
<tr>
<td>Toronto Sample 4</td>
<td>90</td>
<td>EU, AA</td>
<td>0.43</td>
<td>Prospective</td>
<td>Various</td>
<td>PANSS 30% ↓</td>
<td>148 / 57</td>
</tr>
<tr>
<td>Molero et al., 2007</td>
<td>205*</td>
<td>EU</td>
<td>0.46</td>
<td>Naturalistic, Prospective</td>
<td>Various</td>
<td>BPRS 35% ↓</td>
<td>31 / 59</td>
</tr>
<tr>
<td>Pelayo-Teran et al., 2011</td>
<td>99</td>
<td>EU</td>
<td>0.40</td>
<td>Prospective, Randomized</td>
<td>Various</td>
<td>Clozapine</td>
<td>134 / 27</td>
</tr>
<tr>
<td>Porcelli et al., 2009*</td>
<td>144</td>
<td>EU</td>
<td>0.45</td>
<td>Prospective</td>
<td>Various</td>
<td>PANSS 30% ↓</td>
<td>37 / 107</td>
</tr>
<tr>
<td>Toronto Sample 5*</td>
<td>35</td>
<td>EU, AA</td>
<td>0.24</td>
<td>Prospective</td>
<td>Clozapine</td>
<td>BPRS 35% ↓</td>
<td>13 / 22</td>
</tr>
<tr>
<td>Tybura et al., 2012*</td>
<td>179*</td>
<td>EU</td>
<td>0.44</td>
<td>Naturalistic, Randomized</td>
<td>Various</td>
<td>PANSS 30% ↓</td>
<td>90 / 89</td>
</tr>
<tr>
<td>Ikeda et al., 2008*</td>
<td>107*</td>
<td>AS</td>
<td>0.30</td>
<td>Prospective</td>
<td>Risperidone</td>
<td>PANSS 30% ↓</td>
<td>58 / 49</td>
</tr>
</tbody>
</table>

Abbreviations: AA, African American; AS, Asian; BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impressions Scale; EU, European; HS, Hispanic; MAF, minor allele frequency; O, other; PANSS, Positive and Negative Symptom Scale; SI, South Indian.

*Positive and negative sub-scale scores available.
**N reflects additional subjects not included in original publication.

Ethical Considerations

The scientific work described in this article is in compliance with the ethical standards stated in the 1964 Declaration of Helsinki. Informed consent was obtained prior to patient participation, and this work was approved by the Ethics Committee of the Centre for Addiction and Mental Health.

Definition of Clinical Response

Clinical responders and nonresponders were defined based on the criteria applied within each original study separately. If a study did not report the antipsychotic response data in binary responder/nonresponder form, study investigators were contacted and requested to apply a response threshold of 30% change in PANSS score or the equivalent in the clinical rating scale used in their study. The 30% cutoff was adopted for the current study, as it was the most commonly applied criterion in the studies included in the meta-analysis. We used the conversion scale of Leucht et al. (2013) to calculate corresponding response thresholds for other rating scales. For instance, according to this scale, the equivalent score change in the BPRS scale is 35%. For TS54, only responder/nonresponder data were available, for which response was defined as >20% reduction in overall BPRS score after 6 months of treatment based on criteria proposed by Kane et al. (1988). Thus, we had no option but to utilize this response definition for this sample. Overall, 14 of the 15 samples used the 30% PANSS score change (or equivalent) response criteria. Nonclinical dimensions of response, such as improvement in cognition, were not analyzed.

Genotyping

For the Toronto samples, genomic data were extracted using the high-salt method from venous blood (Lahiri and Nurnberger, 1991). The COMT Val158Met (rs4680) variant was genotyped using Taqman 5’ nuclease assay (Applied Biosystems; Foster City, CA). All ambiguous genotypes were retyped. Genotypes that remained ambiguous were excluded from further analyses. Genotyping accuracy was assessed by repeating genotyping for 10% of the sample, and results showed 100% concordance.

Statistical Analysis

All data were analyzed using R statistical software (v3.1.1). Meta-analysis was performed using the ‘meta’ package, version 4.1-0 (Guido Schwarzer, University of Freiburg). Fixed effects models were used for each analysis, consistent with approaches commonly used in pharmacogenetic meta-analyses (Serretti et al., 2007; Zhang et al., 2010). In our primary analysis, separate meta-analyses were conducted assuming three genetic models: recessive (Met/Met vs Val-allele carriers), dominant (Val/Val vs Met-allele carriers), and allelic (Val vs Met allele). All 3 models were used to test the association of COMT Val158Met with numbers of treatment responders vs nonresponders. Odds ratios and 95% CIs were computed and pooled using the Mantel-Haenszel method to determine overall effect sizes. We also examined each genetic model in relation to total symptom score change (%), positive subscale score change (%), and negative subscale score change (%) in a subset of study samples for which data were available (total: studies=10, n=1085; subscases: studies=6, n=516). Effect sizes were analyzed by computing SMD. Heterogeneity was assessed using Cochran’s Q test. Meta-regression was used to check for confounding effects due to the following variables: self-reported ethnicity, SCZ type (first-episode vs non-first episode), antipsychotic type (atypical-only vs mixed; specific drugs), age of onset, sex, study design (eg, prospective, naturalistic), duration of study, drug naive vs prior exposure, and criteria for response. Publication bias was evaluated using the Harbord test (Harbord et al., 2006) and the funnel plot method (“metabias” and “funnel” commands, respectively). Sensitivity analyses were conducted on any significant findings (P <.05) by removing the studies with the largest and smallest effect sizes, as in other antipsychotic pharmacogenetic meta-analyses (Zhang et al., 2010).

To dissect the factors (eg, ancestry, antipsychotic type) contributing to the observed genetic effect, we examined the association between genotype and number of responders/
nonresponders in samples of European ancestry (studies = 10, n_{europe}=929). We focused on this ancestry group, as it constituted the majority of the samples. Ancestry may be important due to significant differences in Val158Met allele frequency between ethnicities. Moreover, since antipsychotic type showed a trend-level association with response, we examined the association between Val158Met and number of responders vs nonresponders in atypical and typical antipsychotic-treated patients separately. 

With regards to correction for multiple testing, our approach is in line with that of prior pharmacogenetic meta-analyses in that we did not correct for the multiple genetic models tested when analyzing single genetic variants due to high correlations between the models (Bakker et al., 2006, 2008; Zhang et al., 2010).

Results

Primary Analyses

We observed a significant association with number of responders/non-responders under the recessive model (Met/Met vs Val-allele carriers) (P = .039, OR_{recessive} = 1.37, 95% CI: 1.02–1.85) (Figure 2; Table 2). We also observed a trend-level association for total score change (P = .087, SMD = 0.14, 95% CI: -0.020–0.30) under a recessive model. Upon examination of the subscales, we observed a significant effect of Val158Met on positive symptom response also under a recessive model (P = .030, SMD = 0.24, 95% CI: 0.024–0.46). No significant associations of Val158Met genotype were observed for any other response measures under any genetic model (all P > .05). The Cochran chi-squared test did not reveal any significant heterogeneity for the recessive model in relation to number of responders/non-responders (P = .37, Q = 15.07, df = 14, I^2 = 7.1%) or for the other genetic models and response measures (all Cochran test P > .05).

Meta-regressions including potential confounding variables revealed a trend for antipsychotic type (atypical-only vs mixed) as a predictor of response rate across studies (P = .055).

Table 2. Primary Analysis Results: All Studies (n=15; total sample size = 1416).

<table>
<thead>
<tr>
<th>Genetic Model</th>
<th>Association Effect Size (Odds Ratio, 95% CI)</th>
<th>Significance (P-Value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recessive</td>
<td>1.37 (1.02–1.85)</td>
<td>0.039*</td>
</tr>
<tr>
<td>Dominant</td>
<td>1.07 (0.83–1.37)</td>
<td>0.58</td>
</tr>
<tr>
<td>Allelic</td>
<td>1.13 (0.96–1.34)</td>
<td>0.14</td>
</tr>
</tbody>
</table>

Abbreviations: M/M, Met/Met genotype; V/M, Val/Met genotype; V/V, Val/Val genotype.
*Denotes significance (P < .05).

Figure 2. All studies. Meta-analysis of the association between the Val158Met polymorphism (Met/Met vs Val carrier) and antipsychotic drug response: forest plot.
We could not include the variable of atypical vs typical antipsychotic-treated samples, as there were no studies with patients exclusively treated with typical antipsychotics. None of the remaining potential confounders tested were associated with response rate: gender, ethnicity, first episode vs non-first episode, treatment duration, study design, age at onset, drug-naïve vs prior exposure, and criteria for response.

Posthoc Analyses

Since the meta-regression revealed antipsychotic type (atypical vs mixed) to be a potential predictor of response ($P = .055$), analyses were conducted separately on patients treated with atypical antipsychotics (studies = 15; $n_{total} = 1207$) and typical antipsychotics (studies = 7; $n_{total} = 155$). The 7 studies with typical antipsychotic-treated patients also included patients treated with atypical antipsychotics, but these were excluded for this analysis. In the subsample of patients treated with atypical antipsychotics, significant differences in the number of responders/non-responders were observed under a recessive genetic model (Met/Met vs Val-allele carriers), whereby patients with Met/Met genotype experienced improved clinical response relative to Val carriers ($P = .0098$, OR = 1.54, 95% CI: 1.11–2.14) (Figure 4; Table 2). Additionally, allelic analyses revealed that the Met-allele was associated with greater likelihood of response compared to Val-allele carriers. The Cochran test showed no significant heterogeneity observed for binary response/nonresponse under the recessive model ($P = .52$, OR = 1.21, 95% CI = 0.85–1.72); however, consistent with whole group analyses, a trend was observed for atypical antipsychotic-treated patients of European ancestry (studies = 10, $n_{total} = 745$) ($P = .061$, OR = 1.45, 95% CI = 0.98–2.15), with Met/Met patients experiencing better response than Val-allele carriers. The Cochran test showed no significant heterogeneity under any of the genetic models (all tests $P > .05$). Furthermore, funnel plot analysis and the Harbord test did not reveal any significant publication bias (supplementary Figure 2).

Discussion

To our knowledge, this study is the most comprehensive meta-analysis to investigate the relationship between COMT Val158Met and antipsychotic clinical response. Our meta-analysis includes data from 8 studies not reported in the original manuscripts and kindly provided to us by the authors (Molero et al., 2007; Ikeda et al., 2008; Gupta et al., 2009; Porcelli et al., 2009; Pelayo-Terán et al., 2011; Gao et al., 2012; Tybura et al., 2012; Bishop et al., 2015), as well as 3 samples previously not investigated for Val158Met and antipsychotic response (TS2, TS3, TS5). Thus, our study provides a much-expanded sample compared with a previous meta-analysis (Chen et al., 2015). More importantly, all samples included in our meta-analysis were analyzed for response/nonresponse according to uniform criteria (PANSS 30% reduction or equivalent), with the exception of one (TS4), minimizing inter-study heterogeneity.

Overall, significant effects of Val158Met on response vs nonresponse, as well as positive symptom improvement, were observed. The association was stronger when restricting the analysis to studies with atypical antipsychotic-treated samples (eg, clozapine, olanzapine, risperidone). Overall, Met-allele homozygotes experienced improved response compared with Val-allele carriers.

These results are consistent with previous studies finding that the Met-allele is associated with improved cognitive response.
to atypical antipsychotics (Bertolino et al., 2004; Weickert et al., 2004; Woodward et al., 2007). These studies evaluated cognitive response using tests such as the Wisconsin Card Sorting Test that evaluate cognitive abilities including working memory, executive function, and attention (Weickert et al., 2004). Conceivably, improvements in clinical symptoms, particularly positive symptoms, may contribute to cognitive improvement. Alternatively, improvements in clinical symptoms may be mediated by improvement in cognitive function (Censits et al., 1997; Velligan et al., 1997; Gold et al., 1999; Hoff et al., 1999); in particular, improved working memory and executive function could lead to improved treatment compliance and adherence to psychiatrist recommendations, resulting in improved clinical outcome. Cognitive response data were available in 3 of the studies included in the meta-analysis. Consistent with previous findings, Bertolino et al. (2004) observed that the Met-allele predicted better working memory response to olanzapine as measured by the N-back task (Bertolino et al., 2004). The 2 other studies did not observe an association between Val158Met and improvement in memory function or cognitive flexibility (Gao et al., 2012) and spatial working memory (Bishop et al., 2015) in response to antipsychotic treatment, respectively. The reasons for this are not clear but may relate to antipsychotic drug-type (both these samples were treated either largely or entirely with risperidone) and cognitive assessment methods (ie, Bishop et al. assessed spatial working memory). However, it should be noted that Gao et al. (2012) observed the same direction effect as previous studies, with the Met-allele appearing to experience greater improvement in orientation, comprehension, and experiential and number memory (Gao et al., 2012).

The findings are also consistent with the tonic-phasic DA hypothesis as applied to antipsychotic response. According to this hypothesis, DA regulation in limbic striatal regions occurs through transient, high-amplitude, phasic DA release and persistent low-level tonic DA release modulated by corticostriatal glutamatergic afferents. In these regions, tonic DA release also

### Table 3. Post Hoc Analysis Results – Atypical and Typical-Antipsychotic Patient Subsamples

<table>
<thead>
<tr>
<th>Genetic Model</th>
<th>Atypical Association Effect Size (Odds Ratio, 95% CI) (n = 1207)</th>
<th>Significance (P-Value)</th>
<th>Typical Association Effect Size (Odds Ratio, 95% CI) (n = 155)</th>
<th>Significance (P-Value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recessive (M/M vs V/M and V/V)</td>
<td>1.54 (1.11–2.14)</td>
<td>0.0098*</td>
<td>0.78 (0.36–1.70)</td>
<td>0.54</td>
</tr>
<tr>
<td>Allelic (M vs V)</td>
<td>1.20 (1.01–1.44)</td>
<td>0.043*</td>
<td>0.78 (0.49–1.22)</td>
<td>0.27</td>
</tr>
</tbody>
</table>

Abbreviations: M/M, Met/Met genotype; V/M, Val/Met genotype; V/V, Val/Val genotype.
*Denotes significance (P < .05).
decreases phasic release through the stimulation of D2 autoreceptors at the synapse (Bilder et al., 2004). Importantly, COMT is involved in modulating the tonic, extracellular pool of DA subcortically, as it breaks down DA that is not reabsorbed by dopamine transporters. Thus, the Met-allele leads to lower COMT activity, higher tonic DA, and lower phasic DA release (more negative symptoms), while the Val-allele gives rise to lower tonic and higher phasic DA release (more positive symptoms) (Bilder et al., 2004). Bilder et al. (2004) have also suggested that D1 receptors are more important for modulating tonic release, while D2 receptors are more critical for regulating phasic DA release (Bilder et al., 2004). Therefore, the COMT Val158Met variant may have different effects on response to different classes of antipsychotics. Specifically, they suggest that the Met-allele may predict better response to agents enhancing D1-transmission (5-HT2A-antagonists and/or 5-HT1A-agonists or partial agonists), since they are thought to increase tonic DA transmission (Bilder et al., 2004). These agents include the majority of atypical antipsychotics. The Val-allele, in contrast, is hypothesized to predict better response to conventional D2-blocking agents (ie, typical antipsychotics), as they decrease phasic DA transmission.

Our findings for positive symptoms may also be consistent with the tonic-phasic DA hypothesis. Based on the predictions of Bilder et al., the Met-allele may also predict improved response in positive symptoms due to lower phasic DA transmission subcortically, which could potentiate the effects of antipsychotic-induced D2 receptor blockade. This prediction is supported by previous findings that the Met-allele is associated with greater dopamine synthesis in the midbrain and thus lower striatal dopaminergic stimulation (Meyer-Lindenberg et al., 2005). Moreover, consistent with this theory, reduced COMT activity has been observed to potentiate clozapine-induced DA release in the prefrontal cortex (PFC) (Tunbridge et al., 2004). By the tonic-phasic DA hypothesis, increased DA release in the PFC leads to greater D1 receptor activation, stimulating greater glutamate release from pyramidal neurons onto the nucleus accumbens. This, in turn, increases tonic DA release, subsequently decreasing phasic DA release and thus reducing positive symptom severity (Bilder et al., 2004). Specific atypical antipsychotics such as risperidone and olanzapine have also been observed to upregulate COMT mRNA expression in the rat PFC (Chen and Chen, 2007), suggesting a direct effect of these drugs on COMT activity.

The observed null genetic effect in typical-antipsychotic-treated patients may be a product of lack of statistical power, as the majority of patients were treated with atypical antipsychotics (typical: n = 155, atypical: n = 1207). Ultimately, it is possible that analyses conducted in larger samples could reveal associations of Val158Met with response in subjects treated with typical antipsychotics. Further, we acknowledge that differences among specific drugs within each class of antipsychotics, rather than broader class differences between atypical and typical antipsychotics, may be driving the results. However, due to limited data, this could not be tested.

The direction of genetic effect was consistent across 11 of the 15 samples in both the analysis of total sample as well as of atypical-antipsychotic-treated patients alone. The four samples observing a genetic effect in the opposite direction included TS1, Molero et al. (2007), Gao et al. (2007), and Ikeda et al. (2008). Notably, these 4 samples’ effects were all nonsignificant (95% CI of OR encompasses 1), leaving open the possibility that the opposite directions of effect may be due to random chance. It is possible that ancestry-related differences in the frequencies of COMT genetic variants other than Val158Met may explain these results. For instance, the functional variant Ala72Ser (rs6267), which is not in LD with Val158Met, also alters COMT activity and exists only in East-Asian populations (MAF: 0.07–0.11) (Gupta et al., 2011). Functional investigations suggest that this variant may exert its effect additively together with Val158Met, whereby presence of both low-activity alleles results in lower COMT activity than possession of either allele alone (Lee et al., 2005). Thus, while ancestry-related differences in MAF and COMT genetic variation may provide insight into the opposite direction of effect observed, we did not have sufficient samples of Asian ancestry to test for ancestry-specific associations. Another sample showing an opposite direction of effect, TS1, was highly treatment-resistant and included only 4 responders compared with 54 nonresponders; this lack of statistical power likely contributed to the null genetic effect observed in this sample. Finally, none of the 4 samples deviated from Hardy-Weinberg equilibrium (HWE) (P < .05), ruling this out as a possible explanation.
In addition, Molero et al. (2007) may have observed a non-significant effect for Val158Met in their sample due to several reasons. First, their sample differed from the majority of other samples in that the study specifically included patients who had recently experienced an acute worsening of psychotic symptoms, leading to uniquely high initial scores (average PANSS score: ~90). Second, the Val-allele carriers had significantly higher PANSS scores compared with Met-allele homozygotes at the study’s beginning. Since baseline score has been observed to predict overall response, this score differential may have contributed to greater score change for Val-allele carriers and thus a higher number of responders. Importantly, Met-allele homozygotes had significantly lower PANSS scores than Val-allele carriers at the end of the 6 months of treatment, which is consistent with findings from other studies in the meta-analysis.

The present meta-analysis had several limitations. First, while we attempted to test and control for possible confounding factors, several factors could not be accounted for due to lack of data availability. These include pharmacological aspects of treatment response, such as drug dose or concentrations, as well as environmental factors, such as significant stress or lifetime exposure to psychosis-inducing drugs. Nevertheless, it should be noted that no confounding effects were observed for the variables tested, except for antipsychotic type (trend observed). Moreover, heterogeneity across studies was not significant for any of the genetic models or response measures evaluated, suggesting minimal confounding by unidentified factors. Second, although we did not observe a significant influence of ethnicity in our samples, it should be noted non-European ethnicities were underrepresented. This imbalance may be important, since, as mentioned previously, Val158Met allele frequencies differ considerably among ethnic groups. Nevertheless, the fact that the sample consisted of mostly patients of European ancestry helps reduce heterogeneity in the sample. Third, it should also be noted that the genotypes in the sample from Pelayo-Teran et al. (2011) were not in HWE ($P < .05$). However, the skewing effect due to non-HWE should be minimal, as removing this sample did not impact the overall genetic effect observed or the level of heterogeneity. Lastly, if we were to apply a Bonferroni correction threshold, the association observed between Val158Met and response, balancing each arm of a RCT so that the same percentage of Met/Met are represented in each arm may prevent COMT genetic imbalance from confounding the efficacy results.

**Acknowledgments**

C.C.Z. is supported by the Brain and Behavior Research Foundation, American Foundation for Suicide Prevention and Eli Lilly. D.F. is supported by the Vanier Canada Graduate Scholarship. D.J.M. has been or is supported by the Canadian Institute of Health Research (CIHR) Operating Grant: “Genetics of antipsychotic-induced metabolic syndrome,” Michael Smith New Investigator Salary Prize for Research in Schizophrenia, NARSAD Independent Investigator Award by the Brain & Behavior Research Foundation, and Early Researcher Award from Ministry of Research and Innovation of Ontario. E.H. is supported by the Canada Graduate Scholarship. H.Y.M. has grant support from Sumitomo Dainippon, Sunovion, Boehringer Ingelheim, Eli Lilly, Janssen, Reviva, Alkermes, Auspex, and FORUM. J.A.L. has received research funding from Alkermes, Biomarin, EnVivo/Forum, Genentech, and Novartis. J.L.K. is supported by the CIHR grant “Strategies for gene discovery in schizophrenia: subphenotypes, deep sequencing and interaction.” J.R.B. is supported by NIH grant MH083888. A.K.T. is supported by a NARSAD Young Investigator Award. J.S. is supported by a P60er independent grant. P.M. receives salary from Clinica Universidade de Navarra and has received research grants from the Ministry of Education (Spain), the Government of Navarra (Spain), the Spanish Foundation of Psychiatry and Mental Health, and AstraZeneca. S.G.P. is supported by the Natural Science Foundation of Ningbo (No. 2009A610186, No. 2013A610249), and the Zhejiang Provincial Medical and Health Project Fund (No. 2015127713). S.G.P. has received research support from Otsuka, Lundbeck, FORUM, and Alkermes.

**Statement of Interest**

H.Y.M. is a shareholder in SureGene, ACADIA, and Glaxo Smith Kline. J.A.L. serves on the Advisory Board of Intracellular Therapies and does not receive direct financial compensation or salary support for his participation. He receives grant support from Alkermes, Biomarin, EnVivo/Forum, Genentech, Novartis/Novation, and Sunovion; is a member of the Advisory Board of Clintara and Pear Therapeutics and holds a financial interest; and holds a patent from Repligen. J.L.K. has acted as a consultant or received honoraria from GlaxoSmithKline, Sanofi-Aventis, Dainippon-Sumitomo, Novartis, Shire, Eli Lilly, and Roche; he is on a Scientific Advisory Board of the Behavior Research Foundation, and Early Researcher Award from the Brain & Behavior Research Foundation or salary support for his participation. He receives grant support. D.J.M. has been or is supported by the Canadian Institute of Health Research (CIHR) Operating Grant: “Genetics of antipsychotic-induced metabolic syndrome,” Michael Smith New Investigator Salary Prize for Research in Schizophrenia, NARSAD Independent Investigator Award by the Brain & Behavior Research Foundation, and Early Researcher Award from Ministry of Research and Innovation of Ontario. E.H. is supported by the Canada Graduate Scholarship. H.Y.M. has grant support from Sumitomo Dainippon, Sunovion, Boehringer Ingelheim, Eli Lilly, Janssen, Reviva, Alkermes, Auspex, and FORUM. J.A.L. has received research funding from Alkermes, Biomarin, EnVivo/Forum, Genentech, and Novartis. J.L.K. is supported by the CIHR grant “Strategies for gene discovery in schizophrenia: subphenotypes, deep sequencing and interaction.” J.R.B. is supported by NIH grant MH083888. A.K.T. is supported by a NARSAD Young Investigator Award. J.S. is supported by a P60er independent grant. P.M. receives salary from Clinica Universidade de Navarra and has received research grants from the Ministry of Education (Spain), the Government of Navarra (Spain), the Spanish Foundation of Psychiatry and Mental Health, and AstraZeneca. S.G.P. is supported by the Natural Science Foundation of Ningbo (No. 2009A610186, No. 2013A610249), and the Zhejiang Provincial Medical and Health Project Fund (No. 2015127713). S.G.P. has received research support from Otsuka, Lundbeck, FORUM, and Alkermes.
boards for Alkermes, Concert, FORUM, Otsuka/Lundbeck, Roche/Gentech, Takeda, Teva, and Vanda, and has served on speakers’ bureaus for Forest, Merck, Novartis, Otsuka, and Sunovion. The remaining authors have no potential conflicts of interests to disclose.

References


Woodward ND, Jayathilake K, Meltzer HY (2007) COMT val108/158Met genotype, cognitive function, and cognitive
improvement with clozapine in schizophrenia. Schizophr Res 90:86–96.